- Open Access
FOXA1 inhibits hepatocellular carcinoma progression by suppressing PIK3R1 expression in male patients
Journal of Experimental & Clinical Cancer Research volume 36, Article number: 175 (2017)
Forkhead box A1 (FOXA1) expression is associated with various types of tumors; however, the function and underlying mechanism of FOXA1 in the development of hepatocellular carcinoma (HCC) remains obscure.
Here, we investigated the role of FOXA1 in the development of HCC by applying gene function gain and loss analysis to HepG2 and Hep3B cell lines, and comparing outcomes with those of clinical HCC samples.
Phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1), which encodes protein PI3Kp85 (p85), was identified as a FOXA1 target gene. Analyses of the mechanism and function revealed that FOXA1 suppresses hepatocellular carcinoma cell viability and motility by inhibiting PI3K/Akt signaling through direct inhibition of PIK3R1 transcription. Moreover, in clinical samples from male HCC patients, FOXA1 expression was much lower, whereas PI3Kp85 levels were much higher in tumor than in non-tumor tissues. Elevated PI3Kp85 is an unfavorable factor in HCC.
As a tumor suppressor, FOXA1 targets PIK3R1 directly to inhibit PI3K/Akt signaling pathway, thus exerting a negative regulatory effect on proliferation, migration, and invasion of HCC in male patients.
Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide [1, 2]. According to data published by the International Agency for Research on Cancer in 2012, over 78 million new cases of HCC and more than 70 million deaths due to HCC are recorded per year. As HCC is a highly heterogeneous disease, several genes and proteins are known to contribute to its tumorigenesis and progression .
Forkhead box A1 (FOXA1), also called HNF3A , is a member of the forkhead family of DNA-binding proteins, which are known for their role in regulating metabolism. FOXA proteins include three members, FOXA1, FOXA2, and FOXA3, each encoded by an individual gene . Increasing evidence indicates that FOXA factors are involved in the development and progression of several tumors .
In the present study, we focused on FOXA1 as a transcriptional regulator of HCC. Function gain and loss analysis was performed to determine the role of FOXA1 in cancer cells derived from male HCC patients.
Human liver carcinoma cell lines HepG2 and Hep3B, both derived from male hepatocellular carcinoma patients according to ATCC, were purchased from the Cell Bank at the Chinese Academy of Sciences (Shanghai, China). According to the manufacturer’s instructions, the cells were cultured in Minimum Essential Medium (MEM; Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco), penicillin (100 U/mL), and streptomycin (100 μg/mL) at 37 °C in a humidified atmosphere containing 5% CO2.
Cells were seeded in 6-well plates (1.5 × 105 or 3 × 105 cells/well) and maintained in complete medium for 12 h prior to transfection with siRNA (GenePharma, Shanghai, China) or plasmid DNA (Vigene Bioscience Inc., Shandong, China). siRNA sequences are available in Additional file 1: Table S1. siRNA and the FOXA1 plasmid were transfected into HepG2 and Hep3B cells at working concentrations of 100 nM using Lipofectamine 3000 (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer’s protocol. Scrambled-sequence siRNA and the pEnter plasmid were transfected as negative controls. Cells were harvested after 48–72 h and used for further experiments.
HepG2 and Hep3B cells were infected with FOXA1-overexpressing lentivirus (GeneChem, Shanghai, China), after which FOXA1 expression was confirmed by quantitative reverse transcription polymerase chain reaction (qPCR) and western blotting.
Quantitative reverse transcription PCR
Trizol reagent (Takara Bio Inc., Shiga, Japan) was used to extract RNA from the cells and total RNA was then reverse transcribed according to the manufacturer’s protocol. PCR cycling conditions were 95 °C for 30 s to denature the cDNA template, followed by 40 cycles at 95 °C for 5 s and 60 °C for 20 s. The specificity of amplification products was confirmed by melting curve analysis. Data were analyzed using the 2−ΔΔCt method. The primers used for qPCR are available in Additional file 1: Table S2. Independent experiments were performed in triplicate.
Cells were lysed using RIPA lysis buffer (Beyotime, Shanghai, China) supplemented with phenylmethylsulfonyl fluoride and phosphatase inhibitors (Roche, Basel, Switzerland). After the protein concentration was determined with the BCA kit (Beyotime), cell lysates were subjected to SDS polyacrylamide gel electrophoresis and the protein bands were transferred to polyvinylidene fluoride membranes. The membranes were then probed with the following primary antibodies: anti-FOXA1 (ab170933; Abcam, Cambridge, UK), PI3Kp85 (ab86714; Abcam), anti-Akt (2920; Cell Signaling Technology, Danvers, MA, USA), anti-phospho-Akt (Ser473, 12,694; Cell Signaling Technology), anti-glyceraldehyde 3-phosphate dehydrogenase (RM2002; Beijing Ray Antibody Biotech, Beijing, China), and anti-Flag (F1804; Sigma, St. Louis, MO, USA). Bands were visualized using horseradish peroxidase-conjugated secondary antibodies and electrochemiluminescence detection kit. All western blot images were processed by ImageJ software (https://imagej.nih.gov/ij/).
Cell proliferation assays
For the Cell Counting Kit-8 (CCK-8) assay, transfected HepG2 and Hep3B cells were seeded in 96-well plates at a density of 103 cells/well. For transient transfection with siFOXA1 and siPIK3R1, cells were cultured for 1, 2, 3, 4, or 5 days. For lentivirus-mediated FOXA1 overexpression, cells were incubated for 1, 2, 3, 4, 5, 6, or 7 days. Subsequently, 100 μL of complete medium supplemented with 10 μL of CCK-8 solution (Dojindo, Kumamoto, Japan) was added to each well, the plates were incubated for 2 h, and the absorbance was measured at 450 nm.
EdU assays: Transfected HepG2 and Hep3B cells were seeded in 96-well plates at a density of 4 × 103 cells/well. After incubation with 10 mM EdU (RiboBio, Guangzhou, China) for 2 h, cells were fixed and stained according to the manufacturer’s protocol. EdU-positive cells were counted under a fluorescence microscope in five random fields.
Colony formation assays: Lentivirus-infected HepG2 and Hep3B cells were seeded in 6-well plates at a density of 300 cells/well and cultured for 14 days. Subsequently, colonies were fixed with 100% methanol and stained with 1% crystal violet. Colonies composed of more than 50 cells in a well were counted under a microscope. All experiments were performed three times.
Migration and invasion assay
For the transwell migration or invasion assay (8.0 μm, #3442; Corning, Corning, NY, USA), 1 × 105 treated cells were seeded into the upper chamber in the presence of an uncoated or a Matrigel-precoated membrane (356,234; Corning) containing 200 μL of serum-free MEM. Complete medium (600 μL) containing 10% FBS was added to the bottom chamber. Following incubation for 24–30 h, the chambers were washed twice with phosphate-buffered saline, fixed with 100% methanol, and stained with 1% crystal violet at room temperature. Cells were counted under a microscope in five random fields.
Chromatin immunoprecipitation (ChIP) assay
To examine whether FOXA1 bound to the promoter sequence of PIK3R1, a ChIP assay (17–371; Millipore, Merck, Darmstadt, Germany) was performed following the manufacturer’s protocol. Briefly, untreated Hep3B cells were fixed using 1% formaldehyde for 10 min to crosslink proteins to DNA, and then soluble chromatin was sheared into 200–1000 bp fragments using sonication. The fragmented chromatin samples were incubated with anti-FOXA1 antibody (ab23738; Abcam) to precipitate the putative binding sequences. Finally, PCR was used to detect enrichment of PIK3R1 promoter fragments on the putative FOXA1 binding sites. Primers used in ChIP are available in Additional file 1: Table S3.
Dual luciferase reporter assay
Hep3B cells were plated at 2 × 105 cells/well in 24-well tissue culture plates. PIK3R1-promoter-pGL3-basic plasmid (Kidan Bio Co. Ltd., Guangzhou, China), pRL-TK plasmid (Kidan Bio Co. Ltd), and FOXA1-pEnter plasmid (Vigene Bioscience Inc.) or pEnter (Vigene Bioscience Inc.) vector were co-transfected into Hep3B cells. After culturing for 48 h, luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega Corporation, Madison, WI, USA).
Immunohistochemistry assays were employed to detect expression of FOXA1 and PI3Kp85 proteins in paraffin-embedded human tissue microarrays (Shanghai Outdo Biotech, Shanghai, China), using a standard immunoperoxidase staining procedure and anti-FOXA1 (1:100, ab170933; Abcam) and anti-PI3Kp85 (1:50, ab86714; Abcam) antibodies. Stained tissue sections were examined separately by two pathologists. Protein expression was evaluated in terms of the proportion and intensity of stained cells. Thus, positive cells were scored based on their staining proportions as 1 (< 25%), 2 (26–50%), 3 (51–75%), and 4 (> 75%); and in terms of intensity as negative (0), weak (1), medium (2), or strong (3).
Computational analysis of putative target genes regulated by FOXA1
Putative target genes controlled by FOXA1 were identified in silico analysis using the Cistrome Dataset Browser (http://cistrome.org/db/#/)  and ChIPBase v2.0 (http://rna.sysu.edu.cn/chipbase/)  databases on ChIP-seq data from HepG2 cells. Genes that scored higher than 2.5 points or encoded proteins were selected for further analysis using the Cistrome Dataset Browser and ChIPBase v2.0, respectively. Gene Ontology (GO) enrichment analysis was employed to cluster predicted genes from the datasets.
SPSS 20.0 software (SPSS Inc. Chicago, IL, USA) was used for statistical analyses. Values represent the mean ± standard error of the mean of at least three independent experiments. Comparisons between two groups were performed using Student’s t-test. Multi-way classification analysis of variance was performed for the results of the CCK-8 assays . Associations between FOXA1 and PI3Kp85 were analyzed using Spearman’s correlation coefficient. Survival analysis was performed using the Kaplan-Meier method. All statistical tests were two-sided, with statistical significance defined as *P < 0.05, **P < 0.01, and ***P < 0.001.
FOXA1 suppresses viability and motility of liver carcinoma cells
To investigate the role of FOXA1 in HCC development, we first investigated the effect of FOXA1 on cell viability and motility in HepG2 and Hep3B cells. HepG2 and Hep3B cells were transduced with siFOXA1 or FOXA1-overexpressing lentiviruses, respectively. To ensure whether the FOXA1 protein expression were consistent with the mRNA expression levels, FOXA1 downregulation and upregulation were confirmed at both mRNA and protein levels through qPCR (Fig. 1a–b) and western blot analysis (Fig. 1c–d) analysis, respectively. Subsequently, the effect of decreased and increased FOXA1 levels on cell proliferation was analyzed using CCK-8, colony formation, and EdU incorporation assays (Figs. 1e–f and 2a–c). Significantly more HepG2 and Hep3B cells were observed following transfection with siFOXA1#1 and siFOXA1#2 than with scramble siRNA. Conversely, FOXA1 overexpression markedly suppressed cell proliferation.
We then investigated the effect of FOXA1 expression on invasion and migration of HepG2 and Hep3B cells in vitro, using a transwell chamber coated with or without Matrigel. FOXA1 downregulation enhanced cell migration and invasion, whereas FOXA1 overexpression blocked HepG2 and Hep3B cell migration and invasion (Fig. 2d–g). Taken together, function gain and loss experiments in hepatocellular carcinoma cell lines revealed that downregulation of FOXA1 accelerated cell proliferation, migration, and invasion, whereas FOXA1 overexpression suppressed the viability and motility of the cells.
FOXA1 directly targets PIK3R1
To explore the mechanism underlying FOXA1 suppression of HCC cell proliferation, migration, and invasion, we searched for FOXA1 target genes in HepG2 cells in Cistrome Dataset Browser and ChIPBase v2.0 databases. In total, 3460 protein-coding genes scoring higher than 2.5 points and 1723 protein-coding genes with significant differences (P < 0.05) were obtained from the Cistrome Dataset Browser and ChIPBase v2.0 databases respectively. Thereafter, 526 FOXA1 target protein-coding genes were collected from the intersection of these 3460 and 1723 genes (Fig. 3a–b). GO enrichment analysis was performed using Cytoscape/BiNGO software to further categorize the 526 FOXA1 target genes. We noticed that PIK3R1 emerged in all of the biological process and molecular function subgroups of GO with significant differences (Fig. 3c–d). Until now, it was reasonable to predict that PIK3R1 was a direct target of FOXA1.
To evaluate the regulatory effect of FOXA1 on PIK3R1, changes in mRNA and protein levels of PIK3R1 were assessed following knockdown or overexpression of FOXA1. Per the qPCR results, PIK3R1 mRNA levels were elevated through FOXA1 downregulation (Fig. 3e), and reduced through FOXA1 overexpression (Fig. 3f) in HepG2 and Hep3B cells. However, western blot analyses also revealed that FOXA1 protein levels were negatively correlated with PI3Kp85 protein levels (Fig. 3g–j) in vitro. Furthermore, phosphorylation of Akt protein increased after silencing of FOXA1, but decreased after FOXA1 overexpression (Fig. 3g–j).
To confirm whether FOXA1 protein directly regulated the transcription of PIK3R1, ChIP and dual luciferase reporter assays were performed using Hep3B cells. Based on the conserved motif of FOXA1 (Fig. 3b), the JASPAR database (http://jaspar.genereg.net/) was used to predict the binding sites of FOXA1 on PIK3R1 promoter sequence. Three sites in the promoter sequence of PIK3R1 were identified and combined with FOXA1 protein through ChIP-PCR (Fig. 4a); furthermore, dual luciferase reporter assays confirmed that FOXA1 directly inhibited PIK3R1 transcription by binding with the promoter sequence of PIK3R1 (Fig. 4b).
In summary, we proved that FOXA1 could directly repress PIK3R1 transcription, thus inhibiting signaling through the PI3K/Akt pathway in HepG2 and Hep3B cells.
PIK3R1 knockdown restores cell viability and motility following FOXA1 downregulation
HepG2 and Hep3B cells transiently co-transfected with siFOXA1 and siPI3KP85 exhibited lower cell proliferation, as revealed by CCK-8 and EdU incorporation assays (Fig. 4c–e). Furthermore, PIK3R1 downregulation significantly inhibited cell migration and invasion as revealed by the transwell assay (Fig. 5a–b). These results indicate that PI3Kp85 knockdown counteracted the increase in cancer cell viability and motility induced by FOXA1 downregulation. Additionally, the levels of phospho-Akt were found to be decreased in co-transfected cells (Fig. 5c).
Pathoclinical features of FOXA1 and PI3Kp85 expression in patients with HCC
Finally, expression of FOXA1 and PI3Kp85 proteins was assessed using a commercial tissue microarray, with paired counterparts, of 90 patients with HCC. The clinical pathological factors and expression of FOXA1, PI3Kp85 in HCC are provided in Additional file 1: Table S4. In male patients, FOXA1 levels were significantly higher in precancerous tissue than in matched HCC tissue; conversely, PI3Kp85 levels were much lower in non-tumor tissue than in tumor tissue (Fig. 5d–e); however, this expression pattern was not observed in female patients. Notably, in male patients with stage II HCC, FOXA1 expression was negatively correlated with PI3Kp85 expression (Fig. 5f and Additional file 1: Table S5), and patients with low expression of PI3Kp85 presented longer survival times (Fig. 5g).
FOXA1 has been linked to various types of tumors [10, 11]. Intriguingly, it exhibits a dual role even in the same pathological condition , partly owing to FOXA1 acting both as a pioneer factor and as a transcription factor [4, 13]. In the latter case, FOXA1 acts as a critical regulator of metabolism, tissue function, and tumor development. In this study, we investigated the role and molecular mechanism of FOXA1 in HCC. Our findings revealed that FOXA1 protein directly regulates transcription of PIK3R1, which encodes PI3Kp85, and blocks HCC proliferation, migration, and invasion. Consistently, in HCC patients, FOXA1 expression was negatively correlated with PI3Kp85 expression in male subjects, and low expression of PI3Kp85 was a favorable factor in stage II male patients with HCC. These results suggest that FOXA1 functions as a potential HCC suppressor.
According to previous studies, FOXA1 is a polytropic gene, often associated with sex hormones . In estrogen receptor-positive breast cancer, prostate cancer , acute myeloid leukemia, and thyroid carcinoma , FOXA1 exhibits a potential cancer-promoting effect; however, it causes tumor inhibition in estrogen receptor-negative breast cancer , advanced prostate cancer, and pancreatic cancer . Further molecular mechanistic studies have revealed that FOXA1 promotes tumor progression by recruiting other transcription factors, while acting as a transcription factor for suppressing tumor development by directly regulating target gene expression [12, 16]. Until now, studies on the role of FOXA1 in carcinogenesis have focused mainly on breast and prostate cancers. Although FOXA1 was first detected in the liver, its role in HCC remains unclear. Recently, Li et al.  demonstrated that the sexual dimorphism of HCC was reversed in Foxa1/Foxa2-deficient mice. Mostly, though, it is believed that FOXA1 and FOXA2 do not interact with each other . The exact mechanism by which FOXA1 regulates HCC progression remains poorly understood.
The PI3K/Akt signaling pathway is well known for mediating fundamental carcinogenic processes, including cancer cell survival, differentiation, proliferation, and motility . The PI3K/Akt signaling pathway is constitutively activated in nearly all cancer types, probably through activation of upstream signaling molecules  or mutation of pathway components . PI3K is composed of a regulatory subunit, PI3Kp85, and a catalytic subunit, PI3Kp110 , whose combination determines the biological activity of PI3K . Recent studies have suggested that PI3Kp85 may act as an oncogene in several tumor types [23, 24], but the role of PI3Kp85 in HCC remains unclear.
In this study, function loss and gain experiments showed that FOXA1 knockdown induced proliferation, migration, and invasion of HepG2 and Hep3B cells, whereas FOXA1 overexpression decreased cell viability and motility. Moreover, the biological functions of FOXA1 identified in this study provide a mechanistic explanation for its role in carcinogenesis. We obtained the FOXA1 putative target gene, PIK3R1, by retrieving information from combined ChIP databases and GO enrichment analysis. Based on the FOXA1 conserved motif, we predicted its binding sites on the PIK3R1 promoter, designed eight pairs of primers to validate the possibility of a successful combination, and observed at least three binding sites. Simultaneously, the luciferase reporter assay indicated that FOXA1 functions as a transcriptional inhibitor of PIK3R1. The reduction in phospho-Akt activity by FOXA1 was mediated by PI3Kp85 and was involved in the PI3K/Akt signaling pathway, as determined by western blotting.
Finally, we confirmed a negative correlation between FOXA1 and PI3Kp85 in stage II male HCC patients, but not in female patients. Moreover, stage II male patients with HCC with low PI3Kp85 were predicted to have a long survival time. This might be linked to the origin of our clinical samples, which were collected from patients with HCC, who underwent surgery, and were in the early stage of the disease. Additionally, it should be noted that both HepG2 and Hep3B cell lines were constructed using samples from Caucasian male patients. These limitations emphasize the importance of investigating the regulatory effects of FOXA1 on PIK3R1 in female patients and in those diagnosed with HCC at different stages. For example, the Mahlavu cell line could be used to investigate how FOXA1 functions in female patients in vitro and more specimens from female patients should be collected to verify the role of FOXA1 in female patients.
In conclusion, this study establishes an important role for FOXA1 in HCC, particularly in male patients. By negatively regulating PIK3R1 transcription, FOXA1 inhibits cell proliferation, migration, and invasion in male patients.
American type culture collection
Phosphoinositide-3-kinase regulatory subunit 1
Faloppi L, Scartozzi M, Maccaroni E, Di Pietro PM, Berardi R, Del PM, Cascinu S. Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options. Cancer Treat Rev. 2011;37:169–77.
Liu Y, Song L, Ni H, Sun L, Jiao W, Chen L, Zhou Q, Shen T, Cui H, Gao T, Li J. ERBB4 acts as a suppressor in the development of hepatocellular carcinoma. Carcinogenesis. 2017;38:465–73.
Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2016;
Jozwik KM, Carroll JS. Pioneer factors in hormone-dependent cancers. Nat Rev Cancer. 2012;12:381–5.
Bochkis IM, Rubins NE, White P, Furth EE, Friedman JR, Kaestner KH. Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress. Nat Med. 2008;14(8):828–36.
Augello MA, Hickey TE, Knudsen KE. FOXA1: master of steroid receptor function in cancer. EMBO J. 2011;30:3885–94.
Mei S, Qin Q, Wu Q, Sun H, Zheng R, Zang C, Zhu M, Wu J, Shi X, Taing L, Liu T, Brown M, Meyer CA, Liu XS. Cistrome data browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse. Nucleic Acids Res. 2017;45:D658–62.
Yang JH, Li JH, Jiang S, Zhou H, ChIPBase QLH. A database for decoding the transcriptional regulation of long non-coding RNA and microRNA genes from ChIP-Seq data. Nucleic Acids Res. 2012;41:D177–87.
Cao C, Sun J, Zhang D, Guo X, Xie L, Li X, Wu D, Liu L. The long intergenic noncoding RNA UFC1, a target of MicroRNA 34a, interacts with the mRNA stabilizing protein HuR to increase levels of beta-catenin in HCC cells. Gastroenterology. 2015;148:415–26.
Song Y, Washington MK, Crawford HC. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res. 2010;70:2115–25.
Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG, Carroll JS. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 2011;30:3019–27.
Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, Sankila A, Turunen JP, Lundin M, Konsti J, Vesterinen T, Nordling S, Kallioniemi O, Hautaniemi S, Janne OA. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J. 2011;30:3962–76.
Chen F, Chen GK, Millikan RC, John EM, Ambrosone CB, Bernstein L, Zheng W, JJ H, Ziegler RG, Deming SL, Bandera EV, Nyante S, Palmer JR, Rebbeck TR, Ingles SA, Press MF, Rodriguez-Gil JL, Chanock SJ, Le Marchand L, Kolonel LN, Henderson BE, Stram DO, Haiman CA. Fine-mapping of breast cancer susceptibility loci characterizes genetic risk in African Americans. Hum Mol Genet. 2011;20:4491–503.
Jin HJ, Zhao JC, Ogden I, Bergan RC, Yu J. Androgen Receptor-Independent function of FoxA1 in prostate cancer metastasis. Cancer Res. 2013;73:3725–36.
Liu YN, Lee WW, Wang CY, Chao TH, Chen Y, Chen JH. Regulatory mechanisms controlling human E-cadherin gene expression. Oncogene. 2005;24:8277–90.
Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y, Qiu J, Liu W, Kaikkonen MU, Ohgi KA, Glass CK, Rosenfeld MG, Reprogramming FX. Transcription by distinct classes of enhancers functionally defined by eRNA. Nature. 2011;474:390–4.
Li Z, Tuteja G, Schug J, Kaestner KH. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell. 2012;148:72–83.
Kanamoto N, Tagami T, Ueda-Sakane Y, Sone M, Miura M, Yasoda A, Tamura N, Arai H, Nakao K. Forkhead box A1 (FOXA1) and A2 (FOXA2) oppositely regulate human type 1 iodothyronine deiodinase gene in liver. Endocrinology. 2012;153:492–500.
Manning BD, Cantley LCAKT. PKB signaling: navigating downstream. Cell. 2007;129:1261–74.
Nandini D. Pradip, Brian LJ. PI3K-AKT-mTOR inhibitors in breast cancers: from tumor cell signaling to clinical trials. Pharmacol Ther. 2017;
Khotskaya YB. Targeting TRK family proteins in cancer. Pharmacol Ther. 2017;173:58–66.
Fritsch R, Downward J. SnapShot: class I PI3K isoform signaling. Cell. 2013;154:940.
Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: eastern cooperative oncology group E2303. Clin Cancer Res. 2014;20:3023–32.
Yu W, Honisch S, Schmidt S, Yan J, Schmid E, Alkahtani S, AlKahtane AA, Alarifi S, Stournaras C, Lang F. Chorein sensitive Orai1 expression and store operated Ca2+ entry in rhabdomyosarcoma cells. Cell Physiol Biochem. 2016;40:1141–52.
This study was supported by the National Natural Science Foundation of China (Grants 81,502,378), the Natural Science Foundation of Guangdong Province (2016A030313533), the Science and Technology Planning Project of Guangdong Province (2016ZC0056), the Science and Technology Foundation of Guangzhou (201604020009), the Scientific Research Foundation for the Returned Overseas Chinese Scholars of Southern Medical University (LX2016N008).
Availability of data and materials
All the data and materials supporting the conclusion are included in this manuscript.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Additional file 1: Table S1.
siRNA used in this study. Table S2 Primers used in qPCR. Table S3 Primers used in ChIP analysis. Table S4 Correlation between clinical pathological factors and expression of FOXA1, PI3Kp85 in HCC Table S5 Specimens exhibit low or high FOXA1 expression in relation to PI3Kp85 expression. (DOCX 25 kb)
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
He, S., Zhang, J., Zhang, W. et al. FOXA1 inhibits hepatocellular carcinoma progression by suppressing PIK3R1 expression in male patients. J Exp Clin Cancer Res 36, 175 (2017). https://doi.org/10.1186/s13046-017-0646-6
- Hepatocellular carcinoma